A Phase 2 interventional study of AKB-6548 and AKB-6548 in Anemia and End Stage Renal Disease, sponsored by Akebia Therapeutics. Completed at 16 sites in United States. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2022-07-01.
Sponsored by Akebia Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing vadadustat in Anemia — 1 open to participants now, 1 under way, none of them phase 3. vadadustat · Anemia.
Among the 27 studies testing vadadustat in Anemia, this one is the 12th largest by enrollment, is one of 3 that started in 2014, is one of 8 in phase 2, and was the 5th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →1 of the 27 studies testing vadadustat in Anemia is open now. Recruiting first, the newest first:
Mackay Memorial Hospital
Ages 18+
vadadustat: first FDA approval 2024 (VAFSEO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2014.
This study's enrollment of 94 is below the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 60 across the 27 interventional studies. Of the 23 that completed or were terminated, 18 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 27 have an industry lead sponsor. The 4 most frequent:
Akebia Therapeutics is the lead sponsor of 37 studies on the registry; 3 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 12 (55%) have results posted.
23 studies in Anemia by Akebia Therapeutics: none open now, none under way, none of them phase 3. Of 20 finished, 16 (80%) have results posted.
Among the 23 studies in Anemia by Akebia Therapeutics, this one is the 10th largest by enrollment, is one of 5 that started in 2014, is one of 9 in phase 2, and was the 6th registered.
Akebia Therapeutics’s Anemia studies by the year they started, since 2010.
None of the studies under way reaches primary completion within a year.
Among the 27 studies testing vadadustat in Anemia, from their registry updates:
Among Akebia Therapeutics’s 23 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the hemoglobin response (efficacy), safety, and tolerability of orally administered AKB-6548 in participants with end stage renal disease undergoing chronic hemodialysis.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AKB-6548
Drug: AKB-6548
Drug: AKB-6548
Starting dose 1. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
Starting dose 2. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
Starting dose 3. Oral dose administered three times weekly for 16 weeks. Dose adjustment based on hemoglobin levels as defined in the protocol.
Change From Pre-dose Average in Hemoglobin (Hgb) Level to The Mid-study Average
Change from pre-dose average was calculated by the mid-study average minus the pre-dose average. The pre-dose average was defined as the average of the 3 Hgb values that were obtained before dosing at the first screening visit, the second screening visit, and the Baseline visit; the mid-study average was defined as the average of the 2 Hgb values that were obtained at the Week 7 and Week 8 visits.
Time frame: Pre-dose (Screening, Second Screening, and Baseline), Week 7, and Week 8
Change From Pre-dose Average in Hgb Level to The End-of-study Average
Change from pre-dose average was calculated by the end-of-study average minus the pre-dose average. The pre-dose average was defined as the average of the 3 Hgb values that were obtained before dosing at the first screening visit, the second screening visit, and the Baseline visit; the end-of-study average was defined as the average of the 2 Hgb values that were obtained at the Week 15 and Week 16 visits.
Time frame: Pre-dose, Week 15, and Week 16
Change From Mid-study Average in Hgb Level to The End-of-study Average
Change from mid-study average was calculated by the end-of-study average minus the mid-study average. The mid-study average was defined as the average of the 2 Hgb values that were obtained at the Week 7 and Week 8 visits; the end-of-study average was defined as the average of the 2 Hgb values that were obtained at the Week 15 and Week 16 visits.
Time frame: Week 7, Week 8, Week 15, and Week 16
Change From Baseline in Hgb
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline Hgb was defined as the average of the three samples obtained prior to dosing.
Time frame: Baseline, Week 4, Week 8, Week 12, and Week 16
Change From Baseline in Hematocrit
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline Hematocrit was defined as the last observation before the first dose of study medication.
Time frame: Baseline, Week 4, Week 8, Week 12, and Week 16
Change From Baseline in Red Blood Cell (RBC) Count
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline RBC Count was defined as the average of the three samples obtained prior to dosing.
Time frame: Baseline, Week 4, Week 8, Week 12, and Week 16
Change From Baseline in Absolute Reticulocyte Count
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline absolute reticulocyte count was defined as the last observation before the first dose of study medication.
Time frame: Baseline, Week 4, Week 8, Week 12, and Week 16
Change From Baseline in Percent Reticulocyte Count
Change from Baseline was calculated as (visit value minus the Baseline value)/ Baseline value x 100. Baseline percent reticulocyte count was defined as the last observation before the first dose of study medication.
Time frame: Baseline, Week 4, Week 8, Week 12, and Week 16
Change From Baseline in Reticulocyte Hgb Content
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline reticulocyte Hgb content was defined as the average of the three samples obtained prior to dosing.
Time frame: Baseline, Week 2, Week 4, Week 8, and Week 16
Change From Baseline in Ferritin
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline ferritin was defined as the last observation before the first dose of study medication.
Time frame: Baseline, Week 4, Week 8, Week 12, and Week 16
Change From Baseline in Hepcidin
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline hepcidin was defined as the last observation before the first dose of study medication.
Time frame: Baseline, Week 8, and Week 16
Change From Baseline in Total Iron-Binding Capacity (TIBC)
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline TIBC was defined as the last observation before the first dose of study medication.
Time frame: Baseline, Week 4, Week 8, Week 12, and Week 16
Change From Baseline in Transferrin Saturation (TSAT)
Change from Baseline was calculated as (visit value minus the Baseline value)/ Baseline value x 100. Baseline TSAT was defined as the last observation before the first dose of study medication.
Time frame: Baseline, Week 4, Week 8, Week 12, and Week 16
Change From Baseline in Iron
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline iron was defined as the last observation before the first dose of study medication.
Time frame: Baseline, Week 4, Week 8, Week 12, and Week 16
Number of Participants Who Received Erythropoiesis-stimulating Agent (ESA) Rescue Therapy
ESA rescue therapy was administered in participants with Hgb ≤12.5 g/dL, and was stopped when Hgb reached ≥13.0 g/dL.
Time frame: Up to Week 16
Number of Participants Who Received Blood Transfusion Rescue Therapy
Blood transfusion rescue therapy was administered in participants with Hgb ≤12.5 g/dL, and was stopped when Hgb reached ≥13.0 g/dL.
Time frame: Up to Week 16
Mean Plasma Concentrations of Vadadustat
Blood samples for determination of plasma levels of Vadadustat were drawn just before and 10 minutes after completion of the dialysis session.
Time frame: Pre-dialysis and post-dialysis on Week 2 and Week 16
Mean Plasma Concentrations of Vadadustat-O-Glucuronide Metabolite
Blood samples for determination of plasma levels of Vadadustat were drawn just before and 10 minutes after completion of the dialysis session.
Time frame: Pre-dialysis and post-dialysis on Week 2 and Week 16
Mean Plasma Concentrations of Vadadustat-Acyl-Glucuronide Metabolite
Blood samples for determination of plasma levels of Vadadustat were drawn just before and 10 minutes after completion of the dialysis session.
Time frame: Pre-dialysis and post-dialysis on Week 2 and Week 16
Number of Participants Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
An adverse event (AE) was defined as any untoward medical occurrence (including a clinically significant abnormal laboratory finding) that occurred in the protocol-specified AE reporting period. A TEAE included medical conditions, signs, and symptoms not previously observed in the participant that emerged during the protocol-specified AE reporting period, including signs or symptoms associated with pre-existing underlying conditions that were not present prior to the AE reporting period. A SAE included AEs that met one or more of the following criteria/outcomes: death, lifethreatening, in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, and congenital anomaly/birth defect.
Time frame: Up to Week 20
Number of Participants With Clinically Significant Changes From Baseline in Vital Signs
Parameters assessed for vital signs included sitting blood pressure, pulse, respiratory rate, and body temperature. The investigator was responsible for reviewing laboratory results for clinically significant changes.
Time frame: Up to Week 20
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values
Parameters assessed for laboratory values included hematology, serum chemistry, urinalysis, iron indices, C-reactive protein, lipid profile, biomarkers, and pregnancy tests. The investigator was responsible for reviewing laboratory results for clinically significant changes.
Time frame: Up to Week 20
Number of Participants With Clinically Significant Abnormal 12-Lead Electrocardiogram (ECG) Findings
A standard 12-lead ECG was performed following dosing in a supine position for approximately 5 minutes. ECGs were taken prior to vital sign assessments, circulatory access cannulation, and blood draws when possible. Clinical significance was determined by the investigator.
Time frame: Up to Week 20
Mean Intravenous Iron Replacement Therapy
Intravenous iron was administered throughout the study to maintain ferritin levels in the range of ≥100 ng/mL to ≤1200 ng/mL.
Time frame: Baseline, Week 8, and Week 16
| Milestone | Vadadustat 300 mg Once Daily (QD) | Vadadustat 450 mg QD | Vadadustat 450 mg 3 Times Per Week (TIW) |
|---|---|---|---|
| Started | 30 | 33 | 31 |
| Completed | 24 | 24 | 21 |
| Not completed | 6 | 9 | 10 |
| Withdrew: Lack of efficacy | 0 | 1 | 6 |
| Withdrew: Adverse event | 3 | 4 | 1 |
| Withdrew: Protocol violation | 0 | 4 | 0 |
| Withdrew: Withdrawal by subject | 3 | 0 | 2 |
| Withdrew: Kidney transplantation | 0 | 0 | 1 |
Change from pre-dose average was calculated by the mid-study average minus the pre-dose average. The pre-dose average was defined as the average of the 3 Hgb values that were obtained before dosing at the first screening visit, the second screening visit, and the Baseline visit; the mid-study average was defined as the average of the 2 Hgb values that were obtained at the Week 7 and Week 8 visits.
| Grams per deciliter (g/dL) | Vadadustat 300 mg Once Daily (QD) | Vadadustat 450 mg QD | Vadadustat 450 mg 3 Times Per Week (TIW) |
|---|---|---|---|
| Pre-dose Average | 10.43 ± 0.645 | 10.55 ± 0.577 | 10.52 ± 0.534 |
| Change from pre-dose average to the mid-study average | 0.00 ± 0.897 | -0.29 ± 0.970 | -0.36 ± 1.134 |
Change from pre-dose average was calculated by the end-of-study average minus the pre-dose average. The pre-dose average was defined as the average of the 3 Hgb values that were obtained before dosing at the first screening visit, the second screening visit, and the Baseline visit; the end-of-study average was defined as the average of the 2 Hgb values that were obtained at the Week 15 and Week 16 visits.
| g/dL | Vadadustat 300 mg Once Daily (QD) | Vadadustat 450 mg QD | Vadadustat 450 mg 3 Times Per Week (TIW) |
|---|---|---|---|
| Pre-dose Average | 10.43 ± 0.645 | 10.55 ± 0.577 | 10.52 ± 0.534 |
| Change From Pre-dose average to The End-of-study Average | -0.03 ± 0.902 | -0.07 ± 0.973 | -0.14 ± 1.123 |
Change from mid-study average was calculated by the end-of-study average minus the mid-study average. The mid-study average was defined as the average of the 2 Hgb values that were obtained at the Week 7 and Week 8 visits; the end-of-study average was defined as the average of the 2 Hgb values that were obtained at the Week 15 and Week 16 visits.
| g/dL | Vadadustat 300 mg Once Daily (QD) | Vadadustat 450 mg QD | Vadadustat 450 mg 3 Times Per Week (TIW) |
|---|---|---|---|
| Mid-study Average | 10.41 ± 0.834 | 10.26 ± 1.167 | 10.19 ± 0.950 |
| Change From Mid-study Average to The End-of-study Average | -0.18 ± 0.512 | 0.16 ± 0.809 | -0.07 ± 0.611 |
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline Hgb was defined as the average of the three samples obtained prior to dosing.
| g/dL | Vadadustat 300 mg Once Daily (QD) | Vadadustat 450 mg QD | Vadadustat 450 mg 3 Times Per Week (TIW) |
|---|---|---|---|
| Baseline | 10.50 ± 0.702 | 10.51 ± 0.755 | 10.50 ± 0.646 |
| Change from Baseline to Week 4 | -0.06 ± 0.708 | -0.21 ± 0.814 | -0.35 ± 0.887 |
| Change from Baseline to Week 8 | -0.14 ± 1.058 | -0.39 ± 1.201 | -0.37 ± 1.386 |
| Change from Baseline to Week 12 | 0.02 ± 0.995 | -0.11 ± 1.087 | -0.06 ± 1.210 |
| Change from Baseline to Week 16 | -0.03 ± 0.946 | -0.13 ± 1.076 | -0.06 ± 1.146 |
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline Hematocrit was defined as the last observation before the first dose of study medication.
| Percentage of red blood cells in blood | Vadadustat 300 mg Once Daily (QD) | Vadadustat 450 mg QD | Vadadustat 450 mg 3 Times Per Week (TIW) |
|---|---|---|---|
| Baseline | 31.2 ± 2.58 | 31.6 ± 3.75 | 31.4 ± 2.75 |
| Change from Baseline to Week 4 | -0.4 ± 2.82 | -1.4 ± 3.36 | -0.7 ± 3.14 |
| Change from Baseline to Week 8 | -1.0 ± 3.87 | -1.6 ± 4.73 | -1.7 ± 4.43 |
| Change from Baseline to Week 12 | -0.2 ± 3.35 | -0.8 ± 4.07 | -0.1 ± 4.35 |
| Change from Baseline to Week 16 | -0.8 ± 3.26 | -1.2 ± 4.19 | -0.2 ± 3.67 |
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline RBC Count was defined as the average of the three samples obtained prior to dosing.
| 10^6 cells per microliter | Vadadustat 300 mg Once Daily (QD) | Vadadustat 450 mg QD | Vadadustat 450 mg 3 Times Per Week (TIW) |
|---|---|---|---|
| Baseline | 3.34 ± 0.278 | 3.49 ± 0.446 | 3.49 ± 0.385 |
| Change from Baseline to Week 4 | -0.06 ± 0.235 | -0.11 ± 0.346 | -0.16 ± 0.276 |
| Change from Baseline to Week 8 | -0.09 ± 0.357 | -0.19 ± 0.482 | -0.16 ± 0.432 |
| Change from Baseline to Week 12 | -0.01 ± 0.325 | -0.14 ± 0.473 | -0.10 ± 0.464 |
| Change from Baseline to Week 16 | -0.05 ± 0.309 | -0.17 ± 0.453 | -0.08 ± 0.412 |
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline absolute reticulocyte count was defined as the last observation before the first dose of study medication.
| 10^6 cells per microliter | Vadadustat 300 mg Once Daily (QD) | Vadadustat 450 mg QD | Vadadustat 450 mg 3 Times Per Week (TIW) |
|---|---|---|---|
| Baseline | 0.0704 ± 0.02548 | 0.0661 ± 0.02300 | 0.0742 ± 0.02777 |
| Change from Baseline to Week 4 | -0.0059 ± 0.02166 | 0.0023 ± 0.02597 | -0.0001 ± 0.02813 |
| Change from Baseline to Week 8 | -0.0054 ± 0.01794 | 0.0041 ± 0.02492 | -0.0018 ± 0.02571 |
| Change from Baseline to Week 12 | 0.0001 ± 0.01592 | 0.0133 ± 0.02734 | 0.0033 ± 0.02479 |
| Change from Baseline to Week 16 | -0.0009 ± 0.02251 | 0.0048 ± 0.02409 | 0.0040 ± 0.02470 |
Change from Baseline was calculated as (visit value minus the Baseline value)/ Baseline value x 100. Baseline percent reticulocyte count was defined as the last observation before the first dose of study medication.
| Percent change | Vadadustat 300 mg Once Daily (QD) | Vadadustat 450 mg QD | Vadadustat 450 mg 3 Times Per Week (TIW) |
|---|---|---|---|
| Baseline | 2.14 ± 0.802 | 1.89 ± 0.572 | 2.19 ± 0.927 |
| Change from Baseline to Week 4 | -0.16 ± 0.578 | 0.14 ± 0.787 | 0.07 ± 0.884 |
| Change from Baseline to Week 8 | -0.15 ± 0.539 | 0.24 ± 0.649 | 0.03 ± 0.710 |
| Change from Baseline to Week 12 | -0.04 ± 0.488 | 0.48 ± 0.704 | 0.17 ± 0.835 |
| Change from Baseline to Week 16 | -0.01 ± 0.586 | 0.23 ± 0.701 | 0.15 ± 0.817 |
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline reticulocyte Hgb content was defined as the average of the three samples obtained prior to dosing.
| μg/dL | Vadadustat 300 mg Once Daily (QD) | Vadadustat 450 mg QD | Vadadustat 450 mg 3 Times Per Week (TIW) |
|---|---|---|---|
| Baseline | 32.39 ± 1.799 | 32.12 ± 1.675 | 30.99 ± 2.372 |
| Change from Baseline to Week 2 | -0.13 ± 1.302 | -0.03 ± 0.972 | 1.01 ± 1.621 |
| Change from Baseline to Week 4 | -0.07 ± 0.859 | -0.21 ± 1.023 | 1.02 ± 1.425 |
| Change from Baseline to Week 8 | 0.41 ± 1.159 | -0.27 ± 1.308 | 1.13 ± 1.301 |
| Change from Baseline to Week 16 | 0.15 ± 1.026 | 0.58 ± 1.284 | -0.18 ± 1.494 |
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline ferritin was defined as the last observation before the first dose of study medication.
| Nanograms per milliliter (ng/mL) | Vadadustat 300 mg Once Daily (QD) | Vadadustat 450 mg QD | Vadadustat 450 mg 3 Times Per Week (TIW) |
|---|---|---|---|
| Baseline | 762.88 ± 470.462 | 781.96 ± 465.148 | 807.75 ± 430.981 |
| Change from Baseline to Week 4 | -48.80 ± 205.733 | -61.21 ± 217.068 | -10.29 ± 254.574 |
| Change from Baseline to Week 8 | 46.85 ± 529.361 | -99.11 ± 240.436 | -48.71 ± 289.063 |
| Change from Baseline to Week 12 | -15.70 ± 316.387 | -61.81 ± 302.719 | 0.92 ± 342.188 |
| Change from Baseline to Week 16 | -56.67 ± 317.098 | -115.36 ± 276.640 | -39.03 ± 484.937 |
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline hepcidin was defined as the last observation before the first dose of study medication.
| Nanograms per milliliter (ng/mL) | Vadadustat 300 mg Once Daily (QD) | Vadadustat 450 mg QD | Vadadustat 450 mg 3 Times Per Week (TIW) |
|---|---|---|---|
| Baseline | 102.59 ± 58.938 | 119.61 ± 54.766 | 105.35 ± 46.805 |
| Change from Baseline to Week 8 | -6.46 ± 49.002 | -27.80 ± 56.752 | -9.14 ± 46.498 |
| Change from Baseline to Week 16 | -15.11 ± 46.526 | -21.66 ± 45.381 | -4.87 ± 50.379 |
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline TIBC was defined as the last observation before the first dose of study medication.
| Micrograms per deciliter (μg/mL) | Vadadustat 300 mg Once Daily (QD) | Vadadustat 450 mg QD | Vadadustat 450 mg 3 Times Per Week (TIW) |
|---|---|---|---|
| Baseline | 204.5 ± 39.72 | 196.7 ± 29.42 | 188.8 ± 32.28 |
| Change from Baseline to Week 4 | 25.7 ± 21.95 | 22.0 ± 32.18 | 18.7 ± 22.39 |
| Change from Baseline to Week 8 | 23.4 ± 28.13 | 30.3 ± 28.30 | 22.0 ± 25.37 |
| Change from Baseline to Week 12 | 30.6 ± 30.05 | 34.8 ± 28.69 | 23.9 ± 19.62 |
| Change from Baseline to Week 16 | 27.7 ± 35.27 | 24.9 ± 29.10 | 25.7 ± 21.78 |
Change from Baseline was calculated as (visit value minus the Baseline value)/ Baseline value x 100. Baseline TSAT was defined as the last observation before the first dose of study medication.
| Percent change | Vadadustat 300 mg Once Daily (QD) | Vadadustat 450 mg QD | Vadadustat 450 mg 3 Times Per Week (TIW) |
|---|---|---|---|
| Baseline | 34.6 ± 11.63 | 33.7 ± 11.14 | 37.5 ± 13.27 |
| Change from Baseline to Week 4 | 5.4 ± 15.49 | 2.1 ± 16.97 | 3.6 ± 15.84 |
| Change from Baseline to Week 8 | 2.9 ± 15.92 | 1.2 ± 17.31 | 3.3 ± 14.87 |
| Change from Baseline to Week 12 | 9.1 ± 19.71 | 1.3 ± 17.18 | 3.7 ± 14.08 |
| Change from Baseline to Week 16 | 2.5 ± 14.86 | 1.7 ± 17.44 | 2.5 ± 13.75 |
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline iron was defined as the last observation before the first dose of study medication.
| μg/dL | Vadadustat 300 mg Once Daily (QD) | Vadadustat 450 mg QD | Vadadustat 450 mg 3 Times Per Week (TIW) |
|---|---|---|---|
| Baseline | 70.6 ± 26.25 | 66.6 ± 23.74 | 75.4 ± 32.31 |
| Change from Baseline to Week 4 | 20.7 ± 32.47 | 18.5 ± 40.91 | 13.3 ± 30.06 |
| Change from Baseline to Week 8 | 14.3 ± 33.38 | 11.6 ± 39.10 | 15.0 ± 30.22 |
| Change from Baseline to Week 12 | 31.7 ± 46.73 | 10.8 ± 31.44 | 15.5 ± 28.01 |
| Change from Baseline to Week 16 | 14.0 ± 34.43 | 10.3 ± 37.16 | 14.0 ± 28.62 |
ESA rescue therapy was administered in participants with Hgb ≤12.5 g/dL, and was stopped when Hgb reached ≥13.0 g/dL.
| Participants | Vadadustat 300 mg Once Daily (QD) | Vadadustat 450 mg QD | Vadadustat 450 mg 3 Times Per Week (TIW) |
|---|---|---|---|
| Number of Participants Who Received Erythropoiesis-stimulating Agent (ESA) Rescue Therapy | 4 | 6 | 2 |
Blood transfusion rescue therapy was administered in participants with Hgb ≤12.5 g/dL, and was stopped when Hgb reached ≥13.0 g/dL.
| Participants | Vadadustat 300 mg Once Daily (QD) | Vadadustat 450 mg QD | Vadadustat 450 mg 3 Times Per Week (TIW) |
|---|---|---|---|
| Number of Participants Who Received Blood Transfusion Rescue Therapy | 1 | 1 | 0 |
Blood samples for determination of plasma levels of Vadadustat were drawn just before and 10 minutes after completion of the dialysis session.
| μg/mL | Vadadustat 300 mg Once Daily (QD) | Vadadustat 450 mg QD | Vadadustat 450 mg 3 Times Per Week (TIW) |
|---|---|---|---|
| Week 2 pre-dialysis | 12.89 ± 13.876 | 17.27 ± 12.741 | 5.329 ± 5.0281 |
| Week 2 post-dialysis | 13.72 ± 13.728 | 18.69 ± 15.601 | 5.287 ± 5.2117 |
| Week 16 pre-dialysis | 11.41 ± 8.7716 | 15.98 ± 12.059 | 4.813 ± 3.6094 |
| Week 16 post-dialysis | 13.85 ± 11.921 | 17.38 ± 12.516 | 3.998 ± 2.9709 |
Blood samples for determination of plasma levels of Vadadustat were drawn just before and 10 minutes after completion of the dialysis session.
| μg/mL | Vadadustat 300 mg Once Daily (QD) | Vadadustat 450 mg QD | Vadadustat 450 mg 3 Times Per Week (TIW) |
|---|---|---|---|
| Week 2 pre-dialysis | 16.66 ± 13.508 | 26.36 ± 21.111 | 6.295 ± 4.8326 |
| Week 2 post-dialysis | 8.725 ± 7.6786 | 13.26 ± 13.154 | 3.101 ± 2.2190 |
| Week 16 pre-dialysis | 15.74 ± 14.356 | 17.19 ± 13.266 | 7.843 ± 8.0807 |
| Week 16 post-dialysis | 7.833 ± 5.5438 | 8.408 ± 6.4361 | 2.998 ± 2.5811 |
Blood samples for determination of plasma levels of Vadadustat were drawn just before and 10 minutes after completion of the dialysis session.
| μg/mL | Vadadustat 300 mg Once Daily (QD) | Vadadustat 450 mg QD | Vadadustat 450 mg 3 Times Per Week (TIW) |
|---|---|---|---|
| Week 2 pre-dialysis | 0.0136 ± 0.00611 | 0.0224 ± 0.01889 | 0.0800 ± NA |
| Week 2 post-dialysis | 0.0142 ± 0.01016 | 0.0095 ± 0.00246 | — |
| Week 16 pre-dialysis | 0.0129 ± 0.01083 | 0.0210 ± 0.00700 | — |
| Week 16 post-dialysis | 0.0100 ± 0.00603 | 0.0087 ± 0.00351 | — |
An adverse event (AE) was defined as any untoward medical occurrence (including a clinically significant abnormal laboratory finding) that occurred in the protocol-specified AE reporting period. A TEAE included medical conditions, signs, and symptoms not previously observed in the participant that emerged during the protocol-specified AE reporting period, including signs or symptoms associated with pre-existing underlying conditions that were not present prior to the AE reporting period. A SAE included AEs that met one or more of the following criteria/outcomes: death, lifethreatening, in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, and congenital anomaly/birth defect.
| Participants | Vadadustat 300 mg Once Daily (QD) | Vadadustat 450 mg QD | Vadadustat 450 mg 3 Times Per Week (TIW) |
|---|---|---|---|
| TEAEs | 26 | 26 | 26 |
| SAEs | 2 | 6 | 5 |
Parameters assessed for vital signs included sitting blood pressure, pulse, respiratory rate, and body temperature. The investigator was responsible for reviewing laboratory results for clinically significant changes.
| Participants | Vadadustat 300 mg Once Daily (QD) | Vadadustat 450 mg QD | Vadadustat 450 mg 3 Times Per Week (TIW) |
|---|---|---|---|
| Number of Participants With Clinically Significant Changes From Baseline in Vital Signs | 0 | 0 | 0 |
Parameters assessed for laboratory values included hematology, serum chemistry, urinalysis, iron indices, C-reactive protein, lipid profile, biomarkers, and pregnancy tests. The investigator was responsible for reviewing laboratory results for clinically significant changes.
| Participants | Vadadustat 300 mg Once Daily (QD) | Vadadustat 450 mg QD | Vadadustat 450 mg 3 Times Per Week (TIW) |
|---|---|---|---|
| Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values | 0 | 0 | 0 |
A standard 12-lead ECG was performed following dosing in a supine position for approximately 5 minutes. ECGs were taken prior to vital sign assessments, circulatory access cannulation, and blood draws when possible. Clinical significance was determined by the investigator.
| Participants | Vadadustat 300 mg Once Daily (QD) | Vadadustat 450 mg QD | Vadadustat 450 mg 3 Times Per Week (TIW) |
|---|---|---|---|
| Number of Participants With Clinically Significant Abnormal 12-Lead Electrocardiogram (ECG) Findings | 0 | 0 | 0 |
Intravenous iron was administered throughout the study to maintain ferritin levels in the range of ≥100 ng/mL to ≤1200 ng/mL.
Results for this outcome have not been posted.
Collected over Up to Week 20 (from the time of the first dose of study medication to last dose + 4 weeks of follow-up). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vadadustat 300 mg Once Daily (QD) | 0/30 (0%) | 5/30 (16.7%) | 22/30 (73.3%) |
| Vadadustat 450 mg QD | 0/33 (0%) | 9/33 (27.3%) | 19/33 (57.6%) |
| Vadadustat 450 mg 3 Times Per Week (TIW) | 0/31 (0%) | 8/31 (25.8%) | 23/31 (74.2%) |
| Event | Vadadustat 300 mg Once Daily (QD) | Vadadustat 450 mg QD | Vadadustat 450 mg 3 Times Per Week (TIW) |
|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 1/30 | 1/33 | 0/31 |
| PneumoniaInfections and infestations | 1/30 | 1/33 | 1/31 |
| Arthritis bacterialInfections and infestations | 1/30 | 0/33 | 0/31 |
| Arteriovenous fistula thrombosisInjury, poisoning and procedural complications | 1/30 | 0/33 | 1/31 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 1/30 | 0/33 | 0/31 |
| Cardiac failure congestiveCardiac disorders | 0/30 | 0/33 | 1/31 |
| DiarrhoeaGastrointestinal disorders | 0/30 | 0/33 | 1/31 |
| Arteriovenous fistula site infectionInfections and infestations | 0/30 | 0/33 | 1/31 |
| Diabetes mellitusMetabolism and nutrition disorders | 0/30 | 0/33 | 1/31 |
| Fluid overloadMetabolism and nutrition disorders | 0/30 | 0/33 | 1/31 |
| Event | Vadadustat 300 mg Once Daily (QD) | Vadadustat 450 mg QD | Vadadustat 450 mg 3 Times Per Week (TIW) |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 4/30 | 4/33 | 2/31 |
| NauseaGastrointestinal disorders | 4/30 | 3/33 | 4/31 |
| Abdominal painGastrointestinal disorders | 2/30 | 4/33 | 0/31 |
| VomitingGastrointestinal disorders | 3/30 | 3/33 | 3/31 |
| Arteriovenous fistula site complicationInjury, poisoning and procedural complications | 3/30 | 0/33 | 0/31 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 3/30 | 2/33 | 1/31 |
| HeadacheNervous system disorders | 3/30 | 2/33 | 3/31 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/30 | 0/33 | 0/31 |
| Hyperparathyroidism secondaryEndocrine disorders | 0/30 | 0/33 | 3/31 |
| HypokalaemiaMetabolism and nutrition disorders | 0/30 | 0/33 | 3/31 |
| Age, Continuous(Years) | Vadadustat 300 mg Once Daily (QD) | Vadadustat 450 mg QD | Vadadustat 450 mg 3 Times Per Week (TIW) | Total |
|---|---|---|---|---|
| Mean | 55.5 ± 12.44 | 59.4 ± 11.62 | 57.8 ± 8.26 | 57.6 ± 10.93 |
| Sex: Female, Male(Participants) | Vadadustat 300 mg Once Daily (QD) | Vadadustat 450 mg QD | Vadadustat 450 mg 3 Times Per Week (TIW) | Total |
|---|---|---|---|---|
| Female | 13 | 15 | 12 | 40 |
| Male | 17 | 18 | 19 | 54 |
| Ethnicity (NIH/OMB)(Participants) | Vadadustat 300 mg Once Daily (QD) | Vadadustat 450 mg QD | Vadadustat 450 mg 3 Times Per Week (TIW) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 14 | 18 | 15 | 47 |
| Not Hispanic or Latino | 16 | 15 | 16 | 47 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Vadadustat 300 mg Once Daily (QD) | Vadadustat 450 mg QD | Vadadustat 450 mg 3 Times Per Week (TIW) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 0 | 1 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 0 | 2 |
| Black or African American | 6 | 9 | 9 | 24 |
| White | 24 | 21 | 19 | 64 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2014 to primary completion in Jul 2015, 10 months.
Results were first posted in Jul 2022, 6 years 11 months after primary completion. A results delay was requested in Oct 2015.
Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 10 months is below that.
Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vadadustat